Kaitlynne N Cunningham (K N Cunningham)

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 7

Top Topics

Atopic Dermatitis

Toll Like Receptor

Drug Administration

Top Venues

American journal of clinical dermatology

Journal of the European Academy of Dermatology and Venereology : JEADV

Journal of cutaneous medicine and surgery

This page only lists publications with an associated author ORCID identifier.

Publications

Kaitlynne N Cunningham, Sarah Alsukait, Christine Learned, Sandhya Deverapalli, Arik Aninos, David Rosmarin
Demographics of Vitiligo in the DataDerm Database. Journal of cutaneous medicine and surgery (2023)
Kaitlynne N Cunningham, David Rosmarin
Vitiligo Treatments: Review of Current Therapeutic Modalities and JAK Inhibitors. American journal of clinical dermatology 24 (2) (2023)
Kaitlynne N Cunningham, David Rosmarin
Vitiligo Treatments: Review of Current Therapeutic Modalities and JAK Inhibitors. American journal of clinical dermatology 24 (2) (2023)
Kaitlynne N Cunningham, David Rosmarin
Vitiligo Treatments: Review of Current Therapeutic Modalities and JAK Inhibitors. American journal of clinical dermatology (2023)
Kaitlynne N Cunningham, Sarah Alsukait, S R Cohen, C Learned, D X Gao, C Kachuk, N Dumont, A Zipeto, David Rosmarin
Apremilast 30 mg twice daily combined with dupilumab for the treatment of recalcitrant moderate-to-severe atopic dermatitis. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Kaitlynne N Cunningham, Sarah Alsukait, Stephanie R Cohen, Christine Learned, David X Gao, Courtney Kachuk, Nicole Dumont, Alysha Zipeto, David Rosmarin
Apremilast 30 mg twice daily combined with dupilumab for the treatment of recalcitrant moderate-to-severe atopic dermatitis. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Kaitlynne N Cunningham, David Rosmarin
Vitiligo Treatments: Review of Current Therapeutic Modalities and JAK Inhibitors. American journal of clinical dermatology 24 (2) (2023)